Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
- Authors
- Nam, Gi-Hoon; Choi, Yoonjeong; Kim, Gi Beom; Kim, Seohyun; Kim, Seong A.; Kim, In-San
- Issue Date
- 12월-2020
- Publisher
- WILEY-V C H VERLAG GMBH
- Keywords
- cancer therapeutics; characterization and clinical-grade exosomes; exosomes; extracellular vesicles; immunotherapy
- Citation
- ADVANCED MATERIALS, v.32, no.51
- Indexed
- SCIE
SCOPUS
- Journal Title
- ADVANCED MATERIALS
- Volume
- 32
- Number
- 51
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/51343
- DOI
- 10.1002/adma.202002440
- ISSN
- 0935-9648
- Abstract
- Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > KU-KIST Graduate School of Converging Science and Technology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.